|Title||Dynorphin A analogs for the treatment of chronic neuropathic pain.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Hall SM, Lee YSun, Hruby VJ|
|Journal||Future Med Chem|
|Keywords||Analgesics, Non-Narcotic, Chronic Disease, Dynorphins, Humans, Neuralgia, Neurotransmitter Agents, Receptors, Bradykinin, Receptors, N-Methyl-D-Aspartate, Receptors, Opioid, kappa, Structure-Activity Relationship|
Chronic pain is one of the most ubiquitous diseases in the world, but treatment is difficult with conventional methods, due to undesirable side effects of treatments and unknown mechanisms of pathological pain states. The endogenous peptide, dynorphin A has long been established as a target for the treatment of pain. Interestingly, this unique peptide has both inhibitory (opioid in nature) and excitatory activities (nonopioid) in the CNS. Both of these effects have been found to play a role in pain and much work has been done to develop therapeutics to enhance the inhibitory effects. Here we will review the dynorphin A compounds that have been designed for the modulation of pain and will discuss where the field stands today.
|Alternate Journal||Future Med Chem|
|PubMed Central ID||PMC4976860|
|Grant List||P01 DA006284 / DA / NIDA NIH HHS / United States |
R01 DA013449 / DA / NIDA NIH HHS / United States
P01DA006284 / DA / NIDA NIH HHS / United States
R01DA013449 / DA / NIDA NIH HHS / United States
Dynorphin A analogs for the treatment of chronic neuropathic pain.
Faculty Member Reference:
Yeon Sun Lee, Ph.D.